多黏菌素B血液吸附治疗内毒素性脓毒性休克(Tigris):多中心、开放标签、贝叶斯随机对照3期试验
Tigris试验为多中心、开放标签、贝叶斯随机对照3期试验,纳入19家美国医院成人脓毒性休克需血管升压药、多器官功能障碍且内毒素活性0.60–0.89单位的患者,按2:1随机接受两次多黏菌素B血液吸附联合标准治疗或单纯标准治疗。主要终点28天病死率:多黏菌素B组39%(41/106) vs 对照组45%(23/51),贝叶斯后验获益概率95.3%(APACHE-II校正OR 0.67,95%可信区间0.39–1.08)。关键次要终点90天病死率后验获益概率99.4%(OR 0.54,95%可信区间0.32–0.87)。安全性方面,多黏菌素B组100例中30例(30%)发生严重不良事件,对照组51例中11例(22%)发生,差异−8个百分点(95%CI −22至6)。作者认为,多黏菌素B血液吸附与28天和90天较低病死率相关的高概率。
要点
- 纳入标准:成人脓毒性休克需血管升压药、多器官功能障碍、内毒素活性0.60–0.89单位。
- 多黏菌素B组28天病死率39%(41/106) vs 对照组45%(23/51),后验获益概率95.3%,APACHE-II校正OR 0.67(95%可信区间0.39–1.08)。
- 90天病死率后验获益概率99.4%,OR 0.54(95%可信区间0.32–0.87)。
- 多黏菌素B组严重不良事件30%(30/100) vs 对照组22%(11/51),差异−8个百分点(95%CI −22至6)。
- 多黏菌素B血液吸附通过血液透析实施,血流速80–120 mL/min,每次90–120分钟,两次间隔22小时。
适用人群与场景
- 成人(年龄≥18岁)脓毒性休克需血管升压药、多器官功能障碍且内毒素活性0.60–0.89单位的患者。
- 研究在19家美国医院进行。
诊断标准与关键阈值
- 内毒素活性0.60–0.89单位。
处置流程与药物剂量
- 多黏菌素B血液吸附通过血液透析实施,血流速80–120 mL/min,每次90–120分钟,两次间隔22小时,联合标准治疗。
研究设计与关键结果
- 多中心、开放标签、贝叶斯随机对照3期试验,19家美国医院,纳入157例(多黏菌素B组106例,对照组51例;女性66例[42%],男性91例[58%])。
- 主要终点28天病死率:多黏菌素B组39%(41/106) vs 对照组45%(23/51),后验获益概率95.3%,APACHE-II校正OR 0.67(95%可信区间0.39–1.08)。
- 关键次要终点90天病死率:后验获益概率99.4%,OR 0.54(95%可信区间0.32–0.87)。
- 安全性:多黏菌素B组100例中30例(30%)发生严重不良事件,对照组51例中11例(22%)发生,差异−8个百分点(95%CI −22至6);多黏菌素B组2例(2%)严重不良事件与治疗相关,1例与多黏菌素B相关,1例与导管置入相关。
证据类型、等级与局限
- 证据类型:多中心、开放标签、贝叶斯随机对照3期试验。
- 研究设计遵循贝叶斯框架,基于早期EUPHRATES试验亚组设定治疗效应先验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对内毒素活性0.60–0.89单位且多器官功能障碍的脓毒性休克成人患者,多黏菌素B血液吸附联合标准治疗与28天和90天较低病死率相关的高概率。
- 多黏菌素B组严重不良事件发生率30%(30/100) vs 对照组22%(11/51),差异−8个百分点(95%CI −22至6)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Endotoxic septic shock, a subset of septic shock with high endotoxin activity and multiorgan failure, is associated with high risk of death. We sought to identify the effect of endotoxin removal from the blood with polymyxin B haemoadsorption on mortality.
METHODS: We conducted an open-label, randomised, controlled, phase 3 trial at 19 US hospitals, enrolling adults (aged ≥18 years) with septic shock requiring vasopressors, with multiple organ dysfunction, and with endotoxin activity between 0·60 and 0·89 units. Patients were randomly assigned (2:1) to receive two sessions of polymyxin B plus standard of care or standard of care alone (control), with block randomisation stratified by site. Study personnel were masked to treatment allocation. Polymyxin B haemoadsorption was given via haemodialysis at a blood flow rate of 80-120 mL/min for 90-120 min per session, 22 h apart. The primary outcome was 28-day mortality in the intention-to-treat cohort. The safety cohort included all participants exposed to any amount of study treatment. Design and analysis followed a Bayesian framework, using a prior for the treatment effect based on a subgroup of the earlier EUPHRATES trial. 90-day mortality was the key secondary outcome. The trial was registered at ClinicalTrials.gov and is completed (NCT03901807).
FINDINGS: Between Sept 30, 2019, and April 10, 2025, we screened 14 890 patients, of whom 157 were enrolled (106 assigned to polymyxin B and 51 to control; 66 [42%] women and 91 [58%] men). At 28 days, 41 (39%) patients in the polymyxin B group and 23 (45%) in the control group had died, yielding a posterior probability of benefit of 95·3% (APACHE-II adjusted odds ratio 0·67 [95% credible interval 0·39-1·08]). At 90 days, the posterior probability of benefit was 99·4% (0·54 [0·32-0·87]). Of 100 patients in the polymyxin B group assessed for safety, 30 (30%) had a serious adverse event compared with 11 (22%) of 51 patients in the control group (difference -8 percentage points [95% CI -22 to 6]). Two (2%) serious adverse events in the polymyxin B group were treatment-related, one related to polymyxin B and one to catheter placement.
INTERPRETATION: In patients with endotoxic septic shock defined by high endotoxin activity and multiorgan failure, polymyxin B haemoadsorption was associated with a high probability of lower mortality at 28 days and 90 days.
FUNDING: Spectral Medical.
参考来源
- Neyra JA, Legrand M, Tidswell MA, et al. Polymyxin B haemoadsorption in endotoxic septic shock (Tigris): a multicentre, open-label, Bayesian, randomised, controlled, phase 3 trial. Lancet Respir Med. 2026. PMID: 41887242. doi:10.1016/S2213-2600(26)00047-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。